Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
alopecia
amenorrhea
arrhythmia, cardiac
autonomic dysfunction
bacterial infection
black box warning
blood pressure
brainstem, lesion of
cancer of colon
carcinoma
cardiomyopathy
cardiotoxicity
cardiovascular disease
cladribine
complications
congestive heart failure
cost effectiveness
echocardiogram
efficacy
ejection fraction
ejection fraction, abnormal
electrocardiogram, abnormal
fingolimod
gammaglobulin therapy, intravenous
heart rate
heart rhythm
iatrogenic neurologic disorders
immunomodulation
immunosuppressive agents
left ventricular dysfunction
leukemia
leukopenia
liver function enzymes
methotrexate
mitoxantrone
mortality
MRI
MRI, abnormal
multiple sclerosis
multiple sclerosis, chronic progressive
multiple sclerosis, relapsing
multiple sclerosis, secondary progressive
multiple sclerosis, treatment of
multiple sclerosis, treatment of, first attack
myocardial injury
myocytolysis
nausea and vomiting
neuromyelitis optica (Devic's disease)
neutropenia
outcome research
practice guidelines
pulmonary edema
review article
safety
sudden death
Takotsubo cardiomyopathy
timolol
treatment of neurologic disorder
urinary tract infection
Showing articles 0 to 18 of 18

Malignancies after Mitoxantrone for Multiple Sclerosis
Neurol 86:2203-2207, Buttmann, M.,et al, 2016

Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015

Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011

Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011

Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010

Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010

Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009

Mitoxantrone as Induction Treatment in aggressive Relapsing Remitting Multiple Sclerosis: Treatment Response Factors in a 5 Year Follow-up Observational Study of 100 Consecutive Patients
JNNP 79:52-56, Le Page,E.,et al, 2008

Four New Cases of Therapy-Related Acute Promyelocytic Leukemia After Mitoxantrone
Neurol 71:457-458, Bosca,I.,et al., 2008

Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007

Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005

Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004

Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004

The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003

Therapy-Related Acute Myeloblastic Leukemia After Mitoxantrone Treatment in a Patient with MS
Neurol 59:954-955, Brassat,D.,et al, 2002

Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002

Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002

Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001



Showing articles 0 to 18 of 18